Tevogen Bio (TVGN) News Today $1.18 +0.02 (+1.72%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$1.17 -0.01 (-0.51%) As of 05/21/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVGN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period D. Boral Capital Reiterates "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)D. Boral Capital reissued a "buy" rating and issued a $10.00 price target on shares of Tevogen Bio in a report on Monday.May 14, 2025 | marketbeat.comTevogen Bio's (TVGN) Buy Rating Reiterated at D. Boral CapitalMay 14, 2025 | americanbankingnews.comTevogen Bio Positions Itself as a Leader in Cost-Efficient Healthcare Amid Global Pharmaceutical CompetitionMay 13, 2025 | nasdaq.comTevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient InnovationMay 12, 2025 | globenewswire.comTevogen Bio Holdings Inc. Announces Letter of Intent with CD8 Technology Services for Cell Therapy Manufacturing FacilityMay 2, 2025 | nasdaq.comTevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder InterestMay 2, 2025 | globenewswire.comD. Boral Capital Reaffirms "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)D. Boral Capital reaffirmed a "buy" rating and set a $10.00 price objective on shares of Tevogen Bio in a report on Tuesday.May 1, 2025 | marketbeat.comCD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million CommitmentApril 30, 2025 | uk.finance.yahoo.comCD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million CommitmentApril 30, 2025 | globenewswire.comTevogen Bio shares surge on revenue forecastApril 29, 2025 | investing.comTevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage AccountsApril 29, 2025 | globenewswire.comTevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor FitzgeraldApril 29, 2025 | globenewswire.comTevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 BillionApril 28, 2025 | globenewswire.comTevogen Bio revises director resignation processApril 27, 2025 | uk.investing.comTevogen Bio past procedure aan voor aftreden bestuurdersApril 26, 2025 | nl.investing.comTevogen Bio Announces 2025 Annual MeetingApril 25, 2025 | globenewswire.comTevogen Bio (NASDAQ:TVGN) Receives "Buy" Rating from D. Boral CapitalD. Boral Capital reiterated a "buy" rating and issued a $10.00 target price on shares of Tevogen Bio in a report on Monday.April 23, 2025 | marketbeat.comTevogen Bio Inc: Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target PredictionApril 18, 2025 | finanznachrichten.deTevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production FacilityApril 17, 2025 | markets.businessinsider.comTevogen Bio Signs Agreement with CD 8 TechnologyApril 17, 2025 | tipranks.comTevogen Bio Secures Agreement with CD8 Technology Services for In-House Cell Therapy Production FacilityApril 17, 2025 | quiverquant.comTevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production FacilityApril 17, 2025 | globenewswire.comTevogen says Databricks commissioned to accelerate PredicTcell developmentApril 16, 2025 | markets.businessinsider.comTevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target PredictionApril 15, 2025 | globenewswire.comTevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor FitzgeraldApril 14, 2025 | globenewswire.comTevogen Bio Holdings: Initiating Sell Rating Based On Pipeline Uncertainty And Cash ConstraintsApril 11, 2025 | seekingalpha.comTevogen announces Tevogen Generics following Trump’s tariff-related statementsApril 10, 2025 | markets.businessinsider.comTevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United StatesApril 9, 2025 | globenewswire.comTevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI BiotechsApril 8, 2025 | globenewswire.comTevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI BiotechsApril 8, 2025 | globenewswire.comTevogen meldt hoog insidersbezit te midden van marktvolatiliteitApril 8, 2025 | nl.investing.comTevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s MissionApril 8, 2025 | markets.businessinsider.comTevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company's MissionApril 7, 2025 | globenewswire.comTevogen Bio (NASDAQ:TVGN) Shares Up 0.9% - Still a Buy?Tevogen Bio (NASDAQ:TVGN) Trading 0.9% Higher - Time to Buy?April 4, 2025 | marketbeat.comTevogen Bio appoints new head of government affairsMarch 27, 2025 | uk.investing.comTevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced ForecastMarch 26, 2025 | globenewswire.comTevogen Bio benoemt nieuwe directeur overheidsrelatiesMarch 26, 2025 | nl.investing.comTevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization PlanMarch 25, 2025 | globenewswire.comNeal Flomenberg Sells 232,968 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) StockTevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) insider Neal Flomenberg sold 232,968 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $1.09, for a total value of $253,935.12. Following the completion of the transaction, the insider now owns 3,595,608 shares of the company's stock, valued at $3,919,212.72. This trade represents a 6.08 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.March 15, 2025 | marketbeat.comTevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Neal Flomenberg Sells 232,968 SharesMarch 15, 2025 | insidertrades.comNeal Flomenberg Sells 70,384 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) StockTevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) insider Neal Flomenberg sold 70,384 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $1.09, for a total transaction of $76,718.56. Following the completion of the sale, the insider now owns 3,898,828 shares of the company's stock, valued at $4,249,722.52. The trade was a 1.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.March 12, 2025 | marketbeat.comTevogen Bio's (TVGN) "Buy" Rating Reaffirmed at D. Boral CapitalD. Boral Capital reissued a "buy" rating and issued a $10.00 price objective on shares of Tevogen Bio in a research note on Tuesday.March 12, 2025 | marketbeat.comTevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Sells $76,718.56 in StockMarch 12, 2025 | insidertrades.comTevogen Bio dient octrooi in voor T-cel-gerichte vaccintechnologieMarch 11, 2025 | nl.investing.comTevogen announces new patent filed for T cell vaccineMarch 11, 2025 | markets.businessinsider.comTevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTOMarch 10, 2025 | globenewswire.comTevogen Bio Holdings Inc. (TVGN) Secures $8M Grant, Accelerates AI Initiatives with MicrosoftMarch 8, 2025 | insidermonkey.comTevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Sells $18,737.92 in StockTevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) insider Neal Flomenberg sold 14,639 shares of the company's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $1.28, for a total transaction of $18,737.92. Following the completion of the sale, the insider now directly owns 4,239,663 shares in the company, valued at approximately $5,426,768.64. The trade was a 0.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.March 8, 2025 | marketbeat.comTevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Sells $97,370.90 in StockTevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) insider Neal Flomenberg sold 88,519 shares of the business's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $1.10, for a total value of $97,370.90. Following the completion of the sale, the insider now directly owns 4,040,485 shares of the company's stock, valued at $4,444,533.50. The trade was a 2.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.March 8, 2025 | marketbeat.comTevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion PanelMarch 7, 2025 | markets.businessinsider.com Get Tevogen Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address TVGN Media Mentions By Week TVGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TVGN News Sentiment▼0.300.65▲Average Medical News Sentiment TVGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TVGN Articles This Week▼03▲TVGN Articles Average Week Get Tevogen Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ardelyx News Today Zymeworks News Today LENZ Therapeutics News Today CureVac News Today CorMedix News Today Chimerix News Today Avid Bioservices News Today Cronos Group News Today Praxis Precision Medicines News Today Nurix Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TVGN) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tevogen Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TVGN Stock Free TVGN Stock Alerts